ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
 

  • P-ISSN2233-4203
  • E-ISSN2093-8950
  • ESCI, SCOPUS, KCI

논문 상세

Home > 논문 상세
  • P-ISSN 2233-4203
  • E-ISSN 2093-8950

Identification of Degradation Products in the Phosphodiesterase (PDE-4) Inhibitor Roflumilast Using High Resolution Mass Spectrometry and Density Functional Theory Calculations

Identification of Degradation Products in the Phosphodiesterase (PDE-4) Inhibitor Roflumilast Using High Resolution Mass Spectrometry and Density Functional Theory Calculations

Mass Spectrometry Letters / Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2015, v.6 no.2, pp.38-42
https://doi.org/10.5478/MSL.2015.6.2.38
Saroj Kumar Paul (Institute of Technical Education and Research (ITER))
Upendra N. Dash (Institute of Technical Education and Research (ITER))
  • 다운로드 수
  • 조회수

Abstract

Roflumilast analogs are a group of drugs which act as selective photodiesterase (PDE-4) inhibitor for the treatment severe chronic pulmonary disease associated with chronic brochnonities. Structural identification of degradation products using high resolution mass spectrometry and theoretical investigation by density functional theory have been successfully carried out on roflumilast to identify four degradation products namely, 3,5-dichloropyridin-4-amine, N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-hydroxy benzamide, N-(3,5-dichloropyridin-4-yl)-3-(cyclopropylmethoxy)-4-(difluoromethoxy) benzamide and 3-(cyclopropylmethoxy)-N- (3,5-dichloro-1-oxidopyridin-4-yl)-4-(difluoro methoxy) benzamide, generated in alkali, acidic and oxidative conditions.

keywords
Roflumilast, Mass Spectrometry, Degradation products, DFT


참고문헌

1

Beghe, B.. (2013). . American Journal of Respiratory and Critical Care Medicine, 188, 271-.

2

Giembycz, Mark, A.. (2010). . Drug Design, Development and Therapy, 4, 147-.

3

Boland, S.. (2014). . Bioorg. Med. Chem. Lett, , -.

4

ICH. (2006). Impurities in New Drug Products Q3B (R2) (-). International Conference on Harmonization Guidance for Industry.

5

ICH. (2003). Stability Testing of New Drug Substances and Products Q1A (R2) (-). International Conference on Harmonization, IFPMA.

6

ICH. (2006). Impurities in New Drug Substances Q3A (R2) (-). International Conference on Harmonization, IFPMA.

7

Tarek, S. B.. (2014). :Bulletin of Faculty of Pharmacy Cairo University.

8

Barhate, V. D.. (2010). . Indian J. Pharm. Sci, 72, 401-.

9

Sun, C.. (2013). . Research on Chemical Intermediates, 1, -.

10

Zhang, H.. (2014). . Journal of Chemical Research, 38, 507-.

11

Lin, Y.. (2013). . Research on Chemical Intermediates, 39, 3111-.

12

Alex, A.. (2009). . Rapid Commun. Mass Spectrom, 23, 2619-.

13

Wright, P.. (2010). . Rapid Commun. Mass Spectrom, 24, 1025-.

14

Wright, P.. (2014). . Rapid Commun. Mass Spectrom, 28, 1127-.

투고일Submission Date
2015-03-18
수정일Revised Date
2015-04-12
게재확정일Accepted Date
2015-04-20
상단으로 이동

Mass Spectrometry Letters